Business
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase
About this update from Uniqure N.v.
[{"type":"text","content":"~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1-ALS ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, May 09, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2023 and highlighted recent progress across its business. “uniQure continued its momentum from a historic 2022 into the first quarter of 2023 as we make progress across all of our corporate objectives,” stated Matt Kapusta, chief executive officer of uniQure. “Our priorities for 2023 include supplying CSL’s launch of HEMGENIX®, advancing the development of AMT-130 in Huntington’s disease, and preparing for the initiation of two new clinical studies in SOD1-ALS and refractory temporal lobe epilepsy. Later in this second quarter of 2023, we look forward to providing a clinical update from our ongoing U.S. Phase I/II study of AMT-130, the first investigational AAV gene therapy in clinical development for Huntington’s disease. This update will help to further guide our clinical development of AMT-130 as we work diligently to bring a disease-modifying treatment option to patients with this devastating neurodegenerative disease.” Recent Updates Commercial launch of HEMGENIX® (etranacogene dezaparvovec-drbl) for the treatment of hemophilia B in the United States and European Union In February 2023, the European Commission granted conditional marketing approval for HEMGENIX®, the first and only one-time gene therapy for the treatment of adults 18 years of age and older living with severe and moderately severe hemophilia B. This follows the November 2022 U.S. marketing approval of HEMGENIX® in adults living with hemophilia B. CSL Behring licensed the exclusive global rights to HEMGENIX® from uniQure in May 2021 and is solely responsible for its commercialization. Following the first commercial sale of HEMGENIX® in the United States, uniQure is entitled to receive a $100.0 million payment from CSL Behring. The Company is also eligible to receive a $75.0 million payment from CSL Behring following the first product sal...